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Summary 
Background: Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving 
adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. 
Objectives: This systematic review evaluated the incidence of VTE in patients with cancer receiving 
neoadjuvant treatment. 
Methods: MEDLINE and EMBASE databases were searched from inception to October 2017. Search 
results were supplemented with screening of conference proceedings of the American Society of 
Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-
2016). Two review authors independently screened titles and abstracts, and extracted data onto 
standardized forms.  
Results: Twenty-eight cohort studies (7827 cancer patients, range 11 to 1398) were included. 
Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal 
cancer representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 
7768 patients were diagnosed with at least one VTE during neoadjuvant treatment for a pooled VTE 
incidence of 7% (95% CI, 5% to 10%) in absence of substantial between study heterogeneity. 
Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as 
pulmonary embolism in 22% to 96% of cases (16 cohorts), and it was symptomatic in 22% to 100% of 
patients (11 cohorts). Highest VTE rates were observed in patients with bladder (10.6%) or 
esophageal (8.4%) cancer. 
Conclusions: This review found a relatively high incidence of VTE in cancer patients receiving 
neoadjuvant therapy in the presence of some between study variation, which deserves further 
evaluation in prospective studies. 
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Essentials 
 Cancer patients are at risk for venous thromboembolism (VTE). 
 The risk of VTE in less advanced stage cancer on neoadjuvant chemotherapy is unclear. 
 In over 7800 patients, we found a 7% pooled incidence of VTE during neoadjuvant therapy. 
 Highest VTE rates were observed in patients with bladder and esophageal cancer. 
 
Introduction 
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a frequent complication in patients with solid or hematological malignancies [1]. 
The pro-coagulant state associated with cancer disease as well as cancer treatments increase the 
risk of VTE up to 50-fold compared to patients without cancer [1-7]. 
Although the risk of VTE has been well described in cancer patients from adjuvant and 
palliative settings, data on the occurrence of VTE in patients receiving neoadjuvant chemo-
radiotherapy remain limited and conflicting [5]. Even though cancer may be considered as less 
extensive in the neoadjuvant setting and therefore amenable of surgical excision, certain tumor 
types with a high thrombogenic potential such as gastric or pancreatic cancer, could activate blood 
coagulation leading to thrombosis [1,8]. In addition, neoadjuvant chemotherapy may increase the 
risk of VTE by directly damaging the endothelium, reducing the levels of blood anticoagulants, and 
increasing tissue factor activity [8]. The occurrence of VTE during these early phases of cancer 
disease may have a significant impact on morbidity, cause the interruption of neoadjuvant 
treatment, delay surgery, and increase health resources utilization and costs.  
Current guidelines suggest the use of VTE thromboprophylaxis in high-risk cancer patients 
receiving adjuvant chemotherapy, whereas no specific recommendations are provided for patients 
undergoing neoadjuvant chemo-radiotherapy [9]. A better understanding of VTE risk during 
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neoadjuvant treatment may inform oncologists about thrombotic risk in these patients, and 
potentially provide useful information to design randomized controlled studies of VTE 
thromboprophylaxis with the aim of reducing this burdensome complication.  
The aim of this review was to summarize the evidence on the risk of VTE in ambulatory 
cancer patients receiving neoadjuvant chemotherapy or chemo-radiotherapy. 
 
Methods 
A systematic search of the literature was conducted in the MEDLINE and EMBASE electronic 
databases (from inception to October 2017). Conference proceedings of the American Society of 
Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-
2016) were screened for potentially relevant records. We used the following search terms as text 
and Mesh words for the search in the electronic databases: "neoadjuvant therapy", "perioperative 
chemotherapy", "thrombosis", "pulmonary embolism", "venous thromboembolism", and "venous 
thrombosis". We applied no language restriction. The search results were supplemented with 
screening of citation lists of related reviews and those of included studies. The review is registered in 
PROSPERO with accession number CRD42017080148. 
 
Study selection 
Prospective or retrospective cohort studies and randomized controlled trials reporting on the 
incidence of VTE during neoadjuvant chemotherapy or chemo-radiotherapy in patients with cancer 
were eligible. We excluded studies reporting on a mix of arterial and venous thrombotic 
complications as well as studies that evaluated the occurrence of VTE over the entire perioperative 
period if the incidence of VTE could not be extracted separately for the pre-surgical neoadjuvant 
phase. In addition, studies occasionally reporting on VTE as one of the adverse effects of 
chemotherapy were not considered as these studies may selectively report only more severe cases 
or fail to properly identify and classify thrombotic events. 
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Two review authors (MDN, MC) independently screened the titles and abstracts identified 
from the searches and any disagreements were resolved through discussion. Studies with 
insufficient information were reevaluated if additional data were made available from the trial 
authors.  
 
Data extraction 
Two review authors (MDN, MC) independently extracted the data from included studies onto 
standardized forms, resolving any disagreements through discussion or by involving a third review 
author (AR). We extracted data on patients’ characteristics (e.g. age, gender), type of cancer and 
neoadjuvant treatment (chemotherapy, radiotherapy, or both), incidence and type of VTE (PE, DVT 
of the lower or upper extremities), presentation of VTE (symptomatic versus incidentally detected), 
and use of thromboprophylaxis during neoadjuvant treatment. The main outcome of interest was 
any VTE, which included symptomatic or incidentally detected DVT and PE. The components of the 
main outcome were considered as secondary outcomes.  
 
Study quality assessment 
For each of the included studies, we evaluated the risk of bias using the Quality In Prognosis Studies 
(QUIPS) tool, which considers six domains to evaluate the validity of and bias in prognostic studies. 
Domains are related to: a) study participation addressing the representativeness of the study 
population; b) attrition bias; c) adequacy of prognostic factor measurement; d) adequacy of 
outcome measurement; e) study confounding, which addresses potential confounding factors, and f) 
appropriateness of statistical analysis and completeness of reporting [10]. Each of these domains 
was rated as at high, moderate, low, or unclear risk of bias. The latter category was only used if 
insufficient details were reported to allow a judgment. We followed guidance as outlined by Hayden 
and colleagues [10], and only described review specific rules for interpretation here. The domain 
“prognostic factor measurement” was considered at “low risk of bias” if information was provided 
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on the type, dose, and duration of neoadjuvant treatment. Regarding the domain related to 
attrition, we anticipated that retrospective cohort studies could select cancer patients undergoing 
surgery after neoadjuvant treatment. Because the evaluation of attrition bias in these circumstances 
would be hampered by the lack of information on withdrawals and patients who did not reach the 
surgical phase, we rated this domain as moderate risk in such studies. The interpretation of the 
domain “adequacy of outcome measurement” was focused on the primary outcome any VTE, and 
considered to be adequate if VTE was objectively diagnosed using reliable and valid reference tests 
in all participants [11]. At the domain related to confounding, we considered the handling of 
potential confounders such as previous VTE, use of central vein catheters, performance status, and 
use of thromboprophylaxis during neoadjuvant treatment. We used the GRADE methodology to 
judge the overall quality of the evidence [12]. 
 
Statistical analysis 
In descriptive analyses, continuous variables were reported as mean (± standard deviations) or 
median (range), categorical variables as number (percentages). Confidence intervals around 
proportions were calculated with the Wilson method. We used univariate random effects logistic 
regression models to summarize VTE incidences as proportions and univariable meta-regression to 
evaluate the effect of cancer type and QUIPS domains. The likelihood ratio test was used to compare 
models with and without a specific covariate. All statistical analyses were conducted using STATA 
version 15.1 (STATACorp LLC, Texas, USA). 
 
Results 
The initial search yielded 944 references. Four additional records were identified by screening of 
conference proceedings and references lists (Figure 1). Following title and abstract screening, 902 
records were excluded and 46 considered potentially eligible. After full-text examination, 18 were 
excluded because outcome data could not be extracted separately for patients receiving 
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neoadjuvant treatment (n = 4), or the article reported a mix of arterial and venous thrombotic 
events (n = 14). Twenty-eight records (19 full-texts and 9 abstracts) including a total study 
population of 7827 cancer patients (range 11 to 1398 patients) were finally included in the review 
(Table 1) [13-40]. All studies but two were single-center [21, 37], and were conducted during a time 
period that spanned from 1994 to 2015. Three studies (10%) had a prospective design [22, 38, 40], 
while all others concerned retrospective cohorts. Overall study quality was modest, with no study 
judged to be at low risk of bias across all QUIPS domains. We adjudicated domains of the QUIPS tool 
as at moderate to high risk of bias in 55% up to 100% of the studies (Table 2).  
Eighteen cohorts included patients with gastrointestinal cancer representing over two-thirds 
of the whole study population (n = 6002, 78%). Eight studies evaluated cancer of the genitourinary 
tract, whereas cancer of the lung, breast and soft tissue were included in one study each. The type of 
neoadjuvant treatment is shown in the Supplementary Table. 
 
Venous thromboembolism during neoadjuvant treatment 
In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment 
for an overall mean VTE incidence of 7% (95% CI, 5% to 10%; moderate quality of evidence due to 
risk of bias). There was low between study heterogeneity, the variation observed was mainly 
attributed to chance (Figure 2). Rates of VTE varied across studies ranging from less than 1% up to 
28% (Figure 2). The highest risk of VTE was observed in patients with bladder (13%;95% CI, 6% to 
21%) or esophageal (7%; 95% CI, 5% to 10%) cancer (Table 3). Figure 3 shows the impact of cancer 
type, study design, and risks of bias in the six QUIPS domains. Although VTE incidence seemed higher 
in genitourinary cancer and in studies at low risk of bias concerning patient participation, the 
evidence was weak. No differences were observed on any of the study quality domains (Figure 3).  
 Sixteen cohorts reported on the site of thrombosis and 11 indicated whether VTE was 
symptomatic or incidentally detected (Table 3). The proportion of patients presenting with PE varied 
between 22% and 96%, whereas that of symptomatic VTE ranged from 22% to 100%, respectively. 
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The majority of symptomatic events were DVTs (38/63). Only 9 of the 25 studies including patients 
with genitourinary or gastrointestinal cancer described the clinical presentation of VTE, which was 
reported to be symptomatic in 42% (91/215). In five of these studies, DVT of the upper or lower 
extremities represented 64% (29/45) of all symptomatic VTEs (Table 3). 
In the study by Krepline and colleagues, 18% of patients with pancreatic cancer were 
receiving or started VTE thromboprophylaxis at time of cancer diagnosis [30]. VTE 
thromboprophylaxis was not provided during neoadjuvant treatment in 15 studies, whereas 
information about the use of thromboprophylaxis was lacking in all other cohorts. 
Three studies adopted a screening strategy for VTE, which included the systematic 
evaluation of patients by compression ultrasonography [18, 22, 38] or computed tomography 
pulmonary angiography [22] before and at the end of neoadjuvant treatment. 
 
Additional observations 
Eight studies reported on the prevalence of VTE before the start of neoadjuvant treatment, which 
ranged between less than 1% up to 10% [17, 21-22, 26, 29-31, 36]. The clinical presentation of 
prevalent VTE was described only by Krepline and colleagues who reported that 69% of these events 
were incidentally detected [30].  
The performance of the Khorana score for the prediction of VTE during neoadjuvant 
treatment was evaluated in two studies [30-31]. In patients with pancreatic cancer, the incidence of 
VTE was 10% (15/155) in patients classified by the Khorana score as at intermediate risk and 11% 
(11/101) in those at high risk [30]. Similar findings were reported in the other study on patients with 
genitourinary cancer (3/28 versus 5/42, respectively) [31].  
No study reported on the incidence of bleeding that occurred either spontaneously or on 
thromboprophylaxis during the neoadjuvant period. In the study of Rulach and colleagues, there 
were 2 fatal and 3 non-fatal bleeding events, which, however, occurred during anticoagulant 
treatment for newly diagnosed VTE. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Discussion 
This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy 
with apparently higher VTE rates for cancer of the bladder or esophagus. Information on the site and 
clinical presentation of VTE was scanty and highly heterogeneous across studies. Two-thirds of the 
study population was represented by patients with gastroesophageal or bladder cancer with limited 
or no data available for cancers at other sites.  
Although VTE represents a common complication in patients with cancer, the risk varies 
markedly among these patients depending on cancer stage and the presence of a number of clinical 
and laboratory risk factors [1,5]. Chemotherapy increases the risk of VTE by two- to six-folds and 
specific chemotherapeutic agents such as platinum-based regimens have been associated with 
higher rates of VTE [2,4,7]. The risk of VTE in patients with a less advanced stage cancer undergoing 
neoadjuvant chemotherapy is less well established. In a study population of over 7,800 patients, we 
found a 7% pooled incidence of VTE, consistent with rates observed in ambulatory cancer patients 
receiving adjuvant treatment [6, 8, 41]. In a recent narrative review of studies on patients with 
esophageal or gastric cancer undergoing neoadjuvant chemotherapy, Marshall-Webb and colleagues 
reported an incidence of VTE ranging between 4% and 19% [42]. The inclusion of studies reporting 
VTE incidence throughout  the neoadjuvant and postoperative periods limits the interpretation of 
their findings. 
The primary site of cancer has been identified as a significant risk factor for VTE across a 
variety of studies [5]. Although specific incidence rates vary based on the clinical setting, cancer 
types consistently associated with the highest rates of VTE include those of the pancreas, stomach, 
uterus, kidney, lung, and primary brain [1,5,43]. These cancer types could be associated with a pro-
coagulant state even when diagnosed at an earlier stage. As two-thirds of the current review 
population was represented by patients with gastrointestinal cancer, the high incidence of VTE 
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observed in our study may be driven by the inclusion of a large proportion of these highly 
thrombogenic cancer types.  
About half of all VTEs diagnosed in cancer patients undergoing adjuvant chemotherapy are 
incidentally detected [44]. Although it is still an area of investigation and debate, data suggest that 
incidental VTE in the cancer population has important prognostic implications and clinical practice 
guidelines recommend the same anticoagulant treatment as for symptomatic VTE [9,45]. In the 
current review, the proportion of patients presenting with an incidental VTE varied across studies, 
where the variation was insufficiently explained by cancer type, study design or risk of bias domains. 
This review has some limitations that need to be acknowledged. Although we used robust 
methods of double and independent risk of bias assessment, poor reporting may have led to some 
misclassifications. For example, clinical presentation of VTE was reported by only one-third of the 
studies, and information on the diagnostic VTE workup was lacking or poorly described. All studies 
included were judged to have significant methodological flaws. The lack of systematic VTE diagnosis 
by an accepted reference method may have introduced significant bias. We found moderate quality 
for the incidence of VTE, where we downgraded the evidence for risk of bias, in the absence of 
substantial inconsistency, imprecision or indirectness. Although study estimates seemed to vary 
across studies and within each cancer type, this was mainly explained by chance. We are moderately 
confident that the actual incidence is close to the estimate, but there is a possibility that it is 
substantially different [12]. Information on study population characteristics and concomitant VTE 
risk factors were scarce, and significant residual confounding cannot be excluded. Most of the 
studies were relatively old and the observed VTE rates may not apply to patients undergoing 
contemporary neoadjuvant treatments. Poor reporting on the use of thromboprophylaxis and 
outcome verification may have resulted in significant underestimation of VTE incidence. Finally, the 
predominant inclusion of gastroesophageal and bladder cancer, limit the generalizability of these 
findings to cancer at other sites.  
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In conclusion, the risk of VTE in cancer patients undergoing neoadjuvant treatments appears 
to be not negligible. Future large prospective studies are warranted to clarify the actual burden of 
VTE and the potential efficacy and safety of VTE thromboprophylaxis in this setting. 
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Title Table 1: Characteristics of included studies. 
Title Table 2: Study design and quality assessment. 
Legend Table 2: *QUIPS: the Quality In Prognosis Studies tool used for risk of bias assessments in 
prognostic studies. Risk of bias is classified as high, moderate, low or unclear.  
Title Table 3: Incidence and clinical presentation of venous thromboembolism. 
Legend Table 3: * 43 PE events, 88 total VTE events; ** Two additional patients had an incidental 
pulmonary embolism, but it is not reported whether these occurred in the neoadjuvant group; 
***Symptomatic VTE reported on 47 patients. CVC-DVT = Central vein catheter DVT; DVT = deep 
vein thrombosis; NR = not reported; PE = pulmonary embolism; VTE = venous thromboembolism. 
Title Supplementary Table: Type of neoadjuvant therapy 
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Title Figure 1: Search results and study selection. 
Title Figure 2: Incidence of venous thromboembolism according to cancer type. 
Title Figure 3: Incidence of venous thromboembolism according to cancer type, study design, and 
risks of bias domains. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
